• Midecamycin in Reliable Cell Assay Workflows

  2026-08-27

  Midecamycin (SKU BA1041) helps researchers design interpretable antibacterial controls around cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects mechanism, concentration selection, solvent compatibility, resistance biology, and practical product-selection criteria to published evidence.

• Mutant Branching Enzyme Improves Pea Starch Function

  2026-08-27

  A 2026 study engineered a Bifidobacterium longum 1,4-α-glucan branching enzyme to reshape pea starch structure and reduce retrogradation and in vitro digestibility. The S321D mutant produced more short branches, increased the slowly digestible fraction, and improved the texture of pea cake after storage, although translation to human glycemic responses remains untested.

• DAPI (hydrochloride): DNA Content in PDAC Studies

  2026-08-26

  DAPI (hydrochloride), also known as 4',6-diamidino-2-phenylindole hydrochloride, converts nuclear DNA content into a quantitative assay endpoint. This guide explains how to apply its fluorescence to PDAC proliferation studies without confusing cell-cycle phenotyping with direct evidence of GOT1 or glutamine-metabolism activity.

• 740 Y-P: Practical PI3K Activation Workflow

  2026-08-26

  740 Y-P is a cell-permeable PI 3-kinase activator for controlled biochemical and cellular studies of PI3K/AKT-associated responses, including vesicular trafficking and neuronal cell survival. It should be used as a research perturbation with model-specific controls, not as a clinical agent or a universally validated activator across unrelated systems.

• AMG 487 CXCR3 Antagonist: Assay Workflow

  2026-08-25

  AMG 487 is a potent, selective CXCR3 antagonist for connecting chemokine binding with calcium signaling, migration, and macrophage polarization. This workflow uses state-aware controls inspired by the LAMP1–CXCL10–CXCR3 axis to improve interpretation in inflammatory assays.

• Coelenterazine: From ROS Signal to Causal Biology

  2026-08-25

  Coelenterazine is a luminescent enzyme substrate for linking ROS biology with luciferase reporter measurements. This article explains how to interpret its signal, adapt it to AVP-axis research, and avoid confusing pathway activity with direct oxidative stress.

• URB597: A Spatial Framework for FAAH Assays

  2026-08-24

  URB597 and KDS-4103 provide a precise way to examine FAAH-dependent anandamide biology. This guide develops a spatial, multimodal assay framework that separates target engagement from receptor effects and clarifies how recent pain research can inform neuroplasticity and neuroinflammation studies.

• IR-820 for Near-Infrared Imaging Workflows

  2026-08-24

  IR-820 (New Indocyanine Green) supports quantitative vascular and tumor imaging through strong near-infrared optical behavior. This guide translates its use from controlled assay development to nanoparticle-enabled photothermal research, with practical setup, calibration, and troubleshooting advice.

• URB597 for Reliable FAAH Assays

  2026-08-23

  Learn how URB597 (SKU A4372; KDS-4103) can improve experimental control when FAAH inhibition intersects with viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers formulation, controls, timing, interpretation, and practical product-selection criteria for endocannabinoid research.

• KIR2.1 Inhibition in Pulmonary Vascular Remodeling

  2026-08-22

  The reference study identifies KIR2.1 as a functional regulator of pulmonary artery smooth muscle cell proliferation and migration in pulmonary hypertension models. Using the inhibitor ML133 alongside a TGF-β1/SMAD2/3 pathway blocker, the authors connect Kir2.1 potassium channel activity with osteopontin, PCNA, and pulmonary vascular remodeling.

• NF 449 for P2X1 Platelet Studies

  2026-08-22

  NF 449 is a high-potency purinergic receptor antagonist for separating ATP-driven P2X1 signaling from broader platelet responses. This practical guide covers platelet activation studies, collagen-induced aggregation assays, concentration selection, and preclinical thrombosis workflows while highlighting key selectivity limits.

• Tropifexor (LJN452) for FXR Barrier Research

  2026-08-21

  Tropifexor (LJN452) enables controlled, low-nanomolar activation of FXR for mechanistic studies of intestinal barrier injury, parenteral nutrition stress, and related metabolic phenotypes. This guide converts recent piglet and patient-derived organoid findings into practical workflows, assay choices, and troubleshooting strategies.

• Safe DNA Gel Stain for Safer Phage Workflows

  2026-08-20

  Safe DNA Gel Stain supports practical DNA and RNA gel visualization when researchers need blue-light compatibility, reduced UV exposure, and a cleaner path to downstream cloning. This guide translates the product into phage-research workflows, from nucleic acid quality control to troubleshooting weak or smeared bands.

• HGFA as a Candidate Biomarker for PAH

  2026-08-20

  The reference study used serum proteomics, ELISA, Mendelian randomization, and animal-model validation to identify hepatocyte growth factor activator (HGFA) as a candidate biomarker for pulmonary arterial hypertension. Its strong diagnostic signal and association with right ventricular measures support further evaluation, while the study design also illustrates how multi-layer validation can strengthen biomarker discovery.

• Oncostatin M in Fibroblast Senescence Assays

  2026-08-19

  Explore how Recombinant Human Oncostatin M can serve as a defined cytokine perturbation in fibroblast senescence research. This article connects OSM response profiling with mitochondrial-quality endpoints highlighted in a recent dermal fibroblast study.

8006 records 1/534 page Next 12345 下5页 Last page